Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: Role of protein kinase A in vascular smooth muscle cell mitogenesis

Biochemical Pharmacology

Volumn 60, Issue 3, 2000, Pages 381-387

  Osinski, Michael T ^a   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Mitogenesis; PDGF; Phosphodiesterases; PKA; Signal transduction; SMC

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHODIESTERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUAZINONE; ROLIPRAM; TREQUINSIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACTIVITY; ENZYME ACTIVATION; MITOGENESIS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RESTENOSIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CATTLE; CELL ADHESION MOLECULES; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA; MICROFILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; THYMIDINE; TRITIUM;

EID: 0034256966     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00328-2     Document Type: Article

References (33)

1. Raines E.W., Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 69:1993;30-37.
2. Ross R., Fuster V. The pathogenesis of atherosclerosis. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1996;441-460 Lippincott-Raven, Philadelphia.
3. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 269:1994;32023-32026.
4. Davis R.J. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 268:1993;14553-14556.
5. Bönisch D., Weber A.-A., Wittpoth M., Osinski M.T., Schrör K. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Mol Pharmacol. 54:1998;241-248.
6. Jonzon B., Nilsson J., Fredholm B.B. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J Cell Physiol. 124:1985;451-456.
7. 1. Exp Cell Res. 160:1985;117-125.
8. 2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol. 37:1990;30-36.
9. 1 in coronary artery smooth muscle cells. Eur J Pharmacol. 345:1998;213-220.
10. Beavo J.A. Cyclic nucleotide phosphodiesterases Functional implications of multiple isozymes . Physiol Rev. 75:1995;725-748.
11. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. 11:1990;150-155.
12. Rose R.J., Liu H., Palmer D., Maurice D.H. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol. 122:1997;233-240.
13. Rascon A., Lindgren S., Stavenow L., Belfrage P., Andersson K.-E., Manganiello V.C., Degermann E. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta. 1134:1992;149-156.
14. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 36:1996;403-427.
15. Schneider H.H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol. 127:1986;105-115.
16. Holck M., Thorens S., Muggli R., Eigenmann R. Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties. J Cardiovasc Pharmacol. 6:1984;520-530.
17. Sheppard H., Wiggan G.A., Tsien W.H. Structure-activity relationship for inhibitors of phosphodiesterases from erythrocytes and other tissues. Adv Cyclic Nucleotide Res. 1:1972;103-112.
18. Reeves M.L., Leigh B.K., England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J. 241:1987;535-541.
19. Chini C.C., Grande J.P., Chini E.N., Dousa T.P. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. J Biol Chem. 272:1997;9854-9859.
20. Kunishima T., Musha H., Eto F., Iwasaki T., Nagashima J., Masui Y., So T., Nakamura T., Oohama N., Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 19:1997;1058-1066.
21. Sekiya M., Funada J., Watanabe K., Miyagawa M., Akatsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 82:1998;144-147.
22. Schröder H., Schrör K. Prostacyclin-dependent cyclic AMP formation in endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 347:1993;101-104.
23. Halbrügge M., Friedrich C., Eigenthaler M., Schanzenbacher P., Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cAMP- and cGMP-elevating vasodilators. J Biol Chem. 265:1990;3088-3093.
24. Makert T., Krenn V., Leebmann J., Walter U. High expression of the focal adhesion- and microfilament-associated protein VASP in vascular smooth muscle and endothelial cells of the intact human vessel wall. Basic Res Cardiol. 91:1996;337-343.
25. Ruppert D., Weithmann K.U. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and platelet aggregation. Life Sci. 31:1982;2037-2043.
26. Souness J.E., Hassall G.A., Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 44:1992;857-866.
27. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 48:1994;827-835.
28. Schoeffter P., Lugnier C., Travo C., Stoclet J.C. A comparison of cyclic AMP signaling system in rat aortic myocytes in primary culture and aorta. Lab Invest. 61:1989;177-182.
29. Dell'aqua M.L., Scott J.D. Protein kinase A anchoring. J Biol Chem. 272:1997;12881-12884.
30. Osinski M.T., Schrör K. Activation of protein kinase A II determines the antimitogenic effect of trapidil. Naunyn-Schmiedebergs Arch Pharmacol. 359:(Suppl):1999;239.
31. Reinitz C.A., Bianco R.A., Shabb J.B. Compartmentation of the type I regulatory subunit of cAMP-dependent protein kinase in cardiac ventricular muscle. Arch Biochem Biophys. 348:1997;391-402.
32. Zhou YY, Cheng H, Bogdanov KY, Hohl C, Altschuld R, Lakatta EG and Xiao RP, Localized cAMP-dependent signaling mediates beta 2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol 273: H1611-1618, 1997.
33. Weber A.-A., Hohlfeld T., Schrör K. cAMP is an important messenger for ADP-induced platelet aggregation. Platelets. 10:1999;238-241.